scholarly journals Erlotinib Induced Severe Acneiform Rash

2021 ◽  
Vol 31 (2) ◽  
pp. 138-141
Author(s):  
Sevda ÖNDER ◽  
Fatma ETGÜ
Keyword(s):  
Acneiform Rash

Oral Isotretinoin for the treatment of Aripiprazol-induced acneiform rash

2018 ◽  
Vol 31 (4) ◽  
pp. e12637 ◽  
Author(s):  
Francisco José Navarro-Triviño ◽  
Pilar de Jaime Ruiz ◽  
Alejandro Porras Segovia ◽  
Valeriano Garrido Torres-Puchol
Keyword(s):  
Acneiform Rash ◽  
Oral Isotretinoin

Facial acneiform rash associated with sorafenib

2009 ◽  
Vol 15 (4) ◽  
Author(s):  
Beatriz Fleta-Asín ◽  
Sergio Vañó-Galván ◽  
Alejandro Ledo-Rodríguez ◽  
Maite Truchuelo-Díez ◽  
Pedro Jaén-Olasolo
Keyword(s):  
Acneiform Rash

Eltrombopag-Associated Acneiform Rash

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Amani M. Cobert ◽  
James G. Wall ◽  
Donald C. Moore
Keyword(s):  
Acneiform Rash

scholarly journals Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Shaad E. Abdullah ◽  
Missak Haigentz ◽  
Bilal Piperdi
Keyword(s):  
Tyrosine Kinase ◽  
Kinase Inhibitors ◽  
Growth Factor Receptor ◽  
Therapeutic Index ◽  
Egfr Inhibitors ◽  
Egfr Inhibition ◽  
Pancreatic Cancers ◽  
Acneiform Rash ◽  
Dermatological Toxicity ◽  
Epidermal Growth

Epidermal growth factor receptor (EGFR) inhibition has now been well established as an effective treatment for various cancers. The EGFR belongs to the ErbB family of tyrosine kinase receptors which regulate tumor cell differentiation, survival and proliferation. Activation of EGFR drives tumorigenesis in lung, head and neck, colorectal and pancreatic cancers. Irrespective of the type of cancer being treated and the mechanism by which tumor EGFR drives tumorigenesis, the major side effect of EGFR inhibition is a papulopustular (also described as maculopapular or acneiform) rash which occurs in about two thirds of treated patients. Interestingly, this rash has been commonly correlated with better clinical outcomes (objective tumor response and patient survival). The pathophysiology of dermatological toxicity from EGFR inhibitors is an important area of clinical research, and the proper management of the rash is essential to increase the therapeutic index from this class of drugs. In this paper, we review the dermatologic toxicities associated with EGFR inhibitors with an emphasis on its pathophysiology and clinical management.

The skin types closely related to development of the facial acneiform rash and the therapeutic effects of EGFR inhibitors in RAS wild-type metastatic colorectal cancer: Ancillary analysis of FAEISS study.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 3637-3637
Author(s):  
Syusuke Yoshikawa ◽  
Naoya Yamazaki ◽  
Yoshio Kiyohara ◽  
Keiko Nozawa ◽  
Haruhiko Fukuda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Topical Corticosteroid ◽  
Metastatic Colorectal Cancer ◽  
Egfr Inhibitors ◽  
Therapeutic Effects ◽  
Egfr Inhibitor ◽  
Wild Type ◽  
Primary Disease ◽  
Acneiform Rash ◽  
Pre Treatment

3637 Background: At ESMO2019, we reported the primary results of a randomized controlled trial (FAEISS study) investigating the efficacy of topical corticosteroid treatment to facial acneiform rash (AR) by EGFR inhibitors comparing groups starting with a very strong topical corticosteroid and the standard weak topical corticosteroid. As an ancillary analysis, we investigated the association between AR and the pre-treatment skin types, as well as between the skin types and therapeutic effects of EGFR inhibitors on the primary disease. Methods: Utilizing pre-treatment clinical photos of the face taken according to the method determined by FAEISS study protocol, we divided the skin types into categories including enlarged pore, oiliness, xerosis, wrinkles, skin color/redness, and allocated the score (1-3) by central review. The severity of AR occurred during the study was graded and was evaluated the association with the specific skin type by Fisher’s exact test. We also investigated the association between the skin types and the best overall response (RECISTv1.1) to EGFR inhibitor therapy on the primary disease using the Cochran-Armitage trend test. Results: Of the registered 172 cases of RAS wild-type metastatic colorectal cancer [104 men and 68 women, median age = 68 (26-79)], omitting the cases with unevaluable data, finally we analyzed 146 cases for associations between the skin types and AR and 147 cases for best overall response. Interestingly, AR developed 13.6% of enlarged pore score 1, 29% of score 2 and 45.8% of score 3, and patients with enlarged pore tended to have more AR (p = 0.058). Surprisingly, the response(CR/PR/SD) of the primary disease were 59.1% of the enlarged pore score 1, 70.6% of score 2 and 87.0% of score 3, and showed statistically significant trend(p < 0.038). Conclusions: This study suggested that a skin type (enlarged pore) is a possible marker predicting AR risk in EGFR inhibitor therapy for RAS wild-type metastatic colorectal cancer, and better therapeutic effects of EGFR inhibitors.

Randomized Double-Blind Trial of Prophylactic Oral Minocycline and Topical Tazarotene for Cetuximab-Associated Acne-Like Eruption

2007 ◽  
Vol 25 (34) ◽  
pp. 5390-5396 ◽  
Author(s):  
Alon Scope ◽  
Anna Liza C. Agero ◽  
Stephen W. Dusza ◽  
Patricia L. Myskowski ◽  
Jocelyn A. Lieb ◽  
...  
Keyword(s):  
Lower Proportion ◽  
Double Blind Trial ◽  
Double Blind ◽  
Acneiform Rash ◽  
The Face ◽  
Grade 3 ◽  
Colorectal Cancer Patients ◽  
To Receive ◽  
Severe Rash ◽  
Cetuximab Therapy

Purpose To evaluate the ability of either oral minocycline, topical tazarotene or both, to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of cetuximab therapy. Patients and Methods Metastatic colorectal cancer patients preparing to initiate cetuximab were randomly assigned to receive daily oral minocycline or placebo, and to receive topical tazarotene application to either left or right side of the face. Both therapies were administered for 8 weeks. Results Forty-eight eligible patients were randomly assigned to minocycline (n = 24) or placebo (n = 24). Total facial lesion counts were significantly lower in patients receiving minocycline at weeks 1 through 4. At week 4, a lower proportion of patients in the minocycline arm reported moderate to severe itch than in the placebo arm (20% v 50%, P = .05). Facial photographs, obtained at week 4, were reviewed for rash global severity. Patients in the minocycline arm trended toward lower frequency of moderate to severe rash than patients receiving placebo (20% v 42%, P = .13). The differences in total facial lesion counts and subjectively assessed itch were diminished by week 8. Cetuximab treatment was interrupted because of grade 3 skin rash in four patients in the placebo arm, and none in the minocycline arm. There was no observed clinical benefit to tazarotene application. Tazarotene treatment was associated with significant irritation, causing its discontinuation in one third of patients. Conclusion Prophylaxis with oral minocycline may be useful in decreasing the severity of the acneiform rash during the first month of cetuximab treatment. Topical tazarotene is not recommended for management of cetuximab-related rash.

Severe Acneiform Rash

2004 ◽  
Vol 8 (6) ◽  
pp. 654-656 ◽  
Author(s):  
Jeannine M. Brant ◽  
Deanna Sanchez Yamamoto ◽  
Pamela Hallquist Viale ◽  
Gary Zhao
Keyword(s):  
Acneiform Rash
Sign in / Sign up

Export Citation Format

Share Document